GlassScriptPhysician profile
Vance G Moore
NPI 1629074885
$3,559.10
in general payments reported to CMS, 2019-2025
28 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $794 · 2021: $611 · 2022: $534 · 2023: $441 · 2024: $453 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,342.61 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $832.69 | 2019-2024 | Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $225.36 | 2019-2025 | Farxiga |
| Abbvie INC. | $114.67 | 2021-2024 | |
| Pfizer INC. | $104.91 | 2019-2024 | |
| Exact Sciences Corporation | $90.29 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $82.04 | 2021-2024 | Jardiance, Emgality |
| Amgen INC. | $81.58 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $70.93 | 2021-2023 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $64.69 | 2022-2024 | Rexulti |
| Sanofi Pasteur INC. | $64.61 | 2019-2025 | |
| Abbott Laboratories | $60.94 | 2021-2023 | Freestyle Libre 2 |
| Dexcom, INC. | $46.37 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $44.79 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Esperion Therapeutics, INC. | $42.19 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $39.66 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $37.61 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $32.69 | 2022-2023 | |
| Ucb, INC. | $32.62 | 2024 | Nayzilam |
| Amarin Pharma, INC. | $27.04 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.88 | 2025 | Gvoke Hypopen |
| Allergan, INC. | $16.40 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.22 | 2020 | |
| Corcept Therapeutics | $15.16 | 2025 | Korlym |
| Eisai INC. | $13.84 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.28 | 2022 | |
| Intra-Sana Laboratories | $12.19 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vance Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.